Voloridge Investment Management LLC bought a new position in SAGE Therapeutics Inc (NASDAQ:SAGE) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 17,524 shares of the biopharmaceutical company’s stock, valued at approximately $2,458,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of SAGE. Wealthcare Advisory Partners LLC raised its holdings in shares of SAGE Therapeutics by 150.0% during the third quarter. Wealthcare Advisory Partners LLC now owns 250 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 150 shares during the last quarter. Point72 Hong Kong Ltd acquired a new stake in SAGE Therapeutics in the 2nd quarter valued at approximately $44,000. Tobam bought a new stake in SAGE Therapeutics during the 2nd quarter valued at $92,000. Tower Research Capital LLC TRC bought a new stake in SAGE Therapeutics during the 2nd quarter valued at $111,000. Finally, Athanor Capital LP acquired a new position in SAGE Therapeutics during the 2nd quarter worth $201,000.
SAGE opened at $149.78 on Wednesday. SAGE Therapeutics Inc has a one year low of $79.88 and a one year high of $193.56. The company has a debt-to-equity ratio of 0.03, a quick ratio of 12.67 and a current ratio of 12.67. The stock’s fifty day moving average is $145.30 and its 200-day moving average is $161.98. The company has a market capitalization of $7.76 billion, a PE ratio of -18.54 and a beta of 2.52.
Several research firms have recently issued reports on SAGE. Stifel Nicolaus reissued a “buy” rating on shares of SAGE Therapeutics in a research note on Wednesday, November 20th. Oppenheimer cut their price objective on shares of SAGE Therapeutics from $200.00 to $190.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Morgan Stanley reaffirmed a “buy” rating and issued a $217.00 price objective on shares of SAGE Therapeutics in a report on Sunday, November 24th. BidaskClub raised shares of SAGE Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, November 21st. Finally, Royal Bank of Canada reiterated a “buy” rating and issued a $235.00 target price on shares of SAGE Therapeutics in a research report on Monday, November 25th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have given a buy rating to the company. SAGE Therapeutics has an average rating of “Buy” and an average price target of $205.44.
SAGE Therapeutics Profile
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).
Recommended Story: What is a balanced fund?
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.